More on GMAB
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $28.87 |
|
|||
| Open | $28.87 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $28.87 | ||||
| Day Low | $28.87 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,284 | ||||
- Genmab and AbbVie say epcoritamab trial missed U.S. survival goal
- Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- TD Cowen Upgrades Genmab A/S (GMAB) to Buy
- Form 6-K GENMAB A/S For: Jul 15
- Darzalex global sales reach $4.2 billion in Q2 2026
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
- H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
- Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,800 at Jefferies
- EU approves Genmab's Tepkinly combo for relapsed follicular lymphoma
- Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Entities mentioned with GMAB
- FDA | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
